Prevent Premature Aging – Pediatric, Adolescent Young Adult Cancer Survivors

Share Button

“…an estimated 16 million cancer survivors who are alive in the United States today…Emerging evidence suggests that these cancer survivors are at risk for premature aging…”

I am the type of long-term cancer survivor discussed in the study below. I am working to prevent premature aging. I wasn’t a pediatric cancer patient. Technically I am classified as an adolescent young adult (AYA) cancer survivor because I was diagnosed at 34.

The issue that long-term cancer survivors share, whether pediatric or AYA, is that 1) we all underwent a tremendous amount of toxicity during our cancer therapies and 2) those toxicities cause a great deal of short, long-term and late stage adverse events. Many of which are fatal eventually.

I’m not writing this post to complain about all of the toxic therapies prescribed by my oncology team…back in 1995. As the saying goes “the cure is worse than the disease.”

This post is about what I do to remain in complete remission from my incurable blood cancer called multiple myeloma, avoid a treatment-related secondary cancer and finally, manage my chemotherapy-induced cardiomyopathy.

Rather than list my anti-angiogenic nutritional regimen, along with my lifestyle therapies such as exercise, whole body hyperthermia, etc. and nutritional supplementation, I will simply say that there are dozens of evidence-based but NON-toxic therapies shown to reduce the risks of MM or cancer in general or are heart healthy. You can say that these therapies prevent premature aging…

If you’d like to learn more about these therapies, scroll down the page, post a question or comment and I will reply to you ASAP.


David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:

Premature Aging in Young Cancer Survivors

“…an estimated 16 million cancer survivors who are alive in the United States today…Emerging evidence suggests that these cancer survivors are at risk for premature aging, manifesting as early onset of chronic health conditions and a higher risk of mortality compared with the general population…

It is estimated that there are currently 16 million cancer survivors alive in the United States today, a number that will exceed 18 million by the year 2022.[1,2] A majority (≥70%) are long-term cancer survivors (alive ≥5 years from diagnosis), and roughly 15% have lived 20 years or more after their diagnosis.[1–3]

For children with cancer, 5-year overall survival now exceeds 80%, and it is projected that by the year 2020 there will be more than 500 000 survivors of childhood cancer living in the United States.[4–6] For patients who undergo hematopoietic cell transplantation (HCT), more than 70% who survive the first 2 years after HCT are expected to become long-term survivors,[7–9]…

Numerous studies, many conducted among elderly (≥65 years old) survivors and some in younger survivor cohorts, have described the high burden of chronic health conditions that develop after cancer treatment, with a well-documented phenotype of premature aging among older survivors[10–14]and a phenotype suggestive of premature aging among younger survivors.[15–18]

In these survivors, there is a dose-dependent effect of treatment that interacts with a priori physiologic health to affect outcomes, whereby the more intensive the cancer-directed treatment or more vulnerable the physiologic state of the patient, the steeper the decline in health and quality of life.[4,10,19]…

High Burden of Chronic Health Conditions in Young Cancer Survivors

Both childhood cancer survivors and young adults treated with HCT are particularly vulnerable to developing chronic health conditions. Although survival rates continue to improve, improvement in lifespan has not always resulted in improvement in other health-related outcomes…

Strategies to Prevent Accelerated Aging in Cancer Patients

Identification of biological processes responsible for accelerated aging among cancer survivors is key to the development of effective pharmaceutical and/or nutriceutical agents to prevent or reverse this pathologic process…

Such interventions may not need to be drastic to be useful: for instance, given the relationship of clonal hematopoiesis to CVD and inflammation, it is possible that preemptive treatment of high-risk patients with anti-inflammatory drugs or drugs used to treat cardiovascular risk factors (eg, hypertension, dyslipidemia) could improve long-term health outcomes…

Airhart et al. recently reported the results of a human pharmacokinetics study, evaluating the therapeutic potential of oral nicotinamide riboside (NR), a pyridine nucleoside form of vitamin B3 found in milk and available as a nutriceutical, to improve blood levels of nicotinamide adenine dinucleotide (NAD+) in humans.[90] NR is converted by NR kinases to nicotinamide mononucleotide. When administered in murine models of impaired mitochondrial oxidative phosphorylation, nicotinamide mononucleotide normalizes an impaired cardiac NADH to NAD+ ratio and improves cardiac function.[90]…

To date, the best-studied interventions to counteract the effects of aging are those aimed at improving health behaviors…


The growing population of cancer survivors around the world calls for an ongoing commitment to studying health outcomes long after the primary cancer treatment has been completed. For young cancer survivors, the burden of chronic health conditions can be substantial, affecting both their healthspan and lifespan. Longitudinal studies are needed to better characterize aging in these survivors, facilitating much-needed interventions to halt or even reverse the trajectory of accelerated aging. These efforts will be enhanced through collaborations between translational researchers, clinical oncologists, primary care providers, geriatricians, patient caretakers, and other stakeholders committed to improving the lives of cancer survivors.”





Leave a Comment: